Profund Advisors LLC Trims Stake in Gilead Sciences, Inc. $GILD

Profund Advisors LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 120,129 shares of the biopharmaceutical company’s stock after selling 5,818 shares during the quarter. Profund Advisors LLC’s holdings in Gilead Sciences were worth $13,334,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Linden Thomas Advisory Services LLC raised its position in Gilead Sciences by 1.6% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 48,274 shares of the biopharmaceutical company’s stock worth $5,358,000 after purchasing an additional 747 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of Gilead Sciences by 4.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 136,002 shares of the biopharmaceutical company’s stock valued at $15,096,000 after buying an additional 6,305 shares during the last quarter. Candriam S.C.A. raised its holdings in shares of Gilead Sciences by 7.3% in the third quarter. Candriam S.C.A. now owns 1,620,397 shares of the biopharmaceutical company’s stock worth $179,864,000 after buying an additional 110,559 shares during the period. RFG Advisory LLC lifted its stake in shares of Gilead Sciences by 1.3% during the 3rd quarter. RFG Advisory LLC now owns 12,922 shares of the biopharmaceutical company’s stock worth $1,434,000 after acquiring an additional 162 shares during the last quarter. Finally, Plato Investment Management Ltd lifted its stake in shares of Gilead Sciences by 15.0% during the 3rd quarter. Plato Investment Management Ltd now owns 51,082 shares of the biopharmaceutical company’s stock worth $5,627,000 after acquiring an additional 6,668 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Up 2.1%

Shares of NASDAQ:GILD opened at $152.50 on Monday. The company has a market capitalization of $189.20 billion, a PE ratio of 23.64, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $93.37 and a 12-month high of $153.13. The business’s fifty day simple moving average is $127.38 and its 200-day simple moving average is $121.04.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. HSBC raised their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This trade represents a 1.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares of the company’s stock, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 373,037 shares of company stock valued at $50,731,512. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.